期刊文献+

培哚普利联合舒洛地特治疗老年早期糖尿病肾病疗效观察 被引量:2

下载PDF
导出
摘要 目的观察培哚普利联合舒洛地特治疗老年早期糖尿病肾病的临床疗效。方法选择糖尿病肾病Ⅳ期患者65例,随机分为对照组和治疗组。对照组在常规治疗的基础上加用培哚普利,治疗组在对照组的基础上增加舒洛地特,8w后测定两组病人空腹血糖(FBG)、24h尿蛋白定量(UAE)、血清胱抑素C(Cystatin C)、甘油三酯(TG)、纤维蛋白原(FIB)的变化。结果治疗组与对照组比较血清胱抑素C、24h尿蛋白定量都有所下降,治疗组比对照组下降更为明显(P<0.05);而甘油三酯、纤维蛋白原只在治疗组有所下降,明显低于对照组(P<0.05或P<0.01)。结论舒洛地特联合培哚普利治疗可通过有效改善老年早期糖尿病肾病而达到延缓肾功能衰竭进展的目的 。
出处 《西南国防医药》 CAS 2010年第5期501-503,共3页 Medical Journal of National Defending Forces in Southwest China
  • 相关文献

参考文献13

  • 1陈宏卫,赖静波,陈新怡,龚维坤,任惠龙.小剂量苯那普利和缬沙坦联合治疗老年早期糖尿病肾病[J].实用老年医学,2006,20(1):34-36. 被引量:4
  • 2Kuriyama S,Tomonar H,Abe A,et al.Beneficial effect of combination therapy with an angiotensinⅡ and angiotensinconverting enzyme inhibitor on overt proteinuria in a patient with type Ⅰdiabetic nephropathy[J].Nephron,2000,86:529-530.
  • 3Mofensen C E,Keane W F,Benntt D H,et al.Prevention of diabetic renal disease with special reference to microal buminuria[J].Lancet,1995,346(3983):1080-1084.
  • 4赵子秀.血清胱蛋白酶抑制剂C测定的临床意义[J].国外医学(泌尿系统分册),2002,22(2):103-104. 被引量:42
  • 5Crook E D,Preddie D C.Relative effects of angiotensin converting enzyme inhibitors and calcium antagonists in advanced diabetic nephropathy[J].Ethn Dis,2004,14(1):87-93.
  • 6Nosadini R,Velussi M,Brocco E,et al.Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenic mechanisms[J].Diabete,2005,54:228-233.
  • 7Benigni A,Gagliardini E,Tomasoni S,et al.Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy[J].Kidney Int,2004,65:2193-2200.
  • 8Ceol M,Gambaro G,Sauer U,et al.Glycosaminoglycan therapy prevents TGF-betal 1 overexpression and pathologic changes in renal tissue of long-term diabetic rats J[J].Am Soc Nephrol,2000,11:2324-2336.
  • 9陈俊,朱秋萍,何雄平,傅爱清.2型糖尿病肾病患者血脂检测的意义[J].现代中西医结合杂志,2008,17(10):1571-1571. 被引量:5
  • 10干正琦,干正琦.2型糖尿病肾病与血脂的相关性分析[J].辽宁实用糖尿病杂志,2004,12(2):27-28. 被引量:18

二级参考文献41

  • 1杨柳 潘家绮 等.-[J].中华医学杂志,2000,80(5):336-336.
  • 2罗邦尧 王笑微 郁忠勤 见:王鸿利 王学锋主编.糖尿病与血栓[A].见:王鸿利,王学锋主编.血栓病临床新技术[C].北京:人民军医出版社,2003..
  • 3Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect [ J ]. Circulation, 2002, 106(6) :672.
  • 4Jerums G, Allen TJ, Gampbell DJ. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria [ J ]. Am J Kidney Dis, 2001,37(5) :890.
  • 5Morgensen CE, Neldama S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotension system in patients with hypertension microalbuminuria and non-insulin dependent diabetes. The Candesartan and lisinopril microalbuminuria ( CLAM ) study [ J ]. BMJ, 2000, 321(7274) : 1440.
  • 6Russo D, Pisani A, Balleta MM, et al. Addictive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy [ J ]. Am J kidney Dis, 1999,33(4) :851.
  • 7[2]Dubois D,Chanson P,Timsit J, et al.Remission of proteinuriafollowing corection of yperlipidemia in NIDDM patients with nondiabetic glomerulopathy.DIabetes Care 1994;17:906.
  • 8Sowers JR, Lester MA. Diabetes and cardiovascular disease [J]. Diabetes Care, 1999,22:14 - 20.
  • 9Reid HL, Vigilanee JW Pasooe RA, et al. The influence of persistent hyperglycaernia on hyperfiberinogenomia and hypervisoosity in diabetes mellitus [J ]. West Indian Medical Journal,2000,49(4) :281-284.
  • 10Adelstein S,Gomperts ED, Joffe BI, et al. Haemostatic factors in black and white diabetics[J]. S Air Med J, 1999,55 :325 - 328.

共引文献115

同被引文献29

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部